Bispecific antibodies can target surface-expressed tumor antigens and one effector cell antigen (such as CD3 for lymphocytes or CD56 for NK cells) and exploit bystander immune cells in order to target tumor cells in a MHC-independent fashion, similarly to CAR-engineered cells. The gene discussed is NCAM1; the disease is neoplasm.